Discover Camcevi. Zero Cancer Run/Walk, June 10, 2023, Mokeno, IL
site-logo
AVAILABLE
TO ORDER
 

This site is intended for use by U.S. residents only.

©2023 CAMCEVI. All rights reserved. WS-CAM-2200004 V7

Coverage Finder

Contacting the patient's health plan or submitting a benefits verification is encouraged as actual coverage could vary based on the member's benefit design. Call (866) 258-7151.

To find CAMCEVI coverage information, select coverage type and state below. Results will appear automatically.

Insurance Coverage Type State Status Restrictions

    ×
    Source: Managed Markets Insight & Technology, LLC

    Individual costs and benefit design may vary. Please consult with individual plans for specific information. Reimbursement is circumstantial and this information does not represent a reimbursement guarantee.

    *Prior Authorization (PA), Step Therapy (ST) and Quantity Limit (QL)

    View All / Print

    Get Prior Authorization Support

    Coordinators at AccordCares™ are available to assist with acquiring prior authorization from plan providers. Call (866) 258-7151

    Learn more

    Verify Patient Benefits

    Determine if your patient is covered in three easy steps. Complete section 1, 2, and 3 of enrollment form. Get answers within 2 days.

    Download form

      GET UPDATES

      Stay informed about
      CAMCEVI with regular updates,
      education, and more.

      *Required fields

      IMPORTANT SAFETY INFORMATION

      Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

      CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction, spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.

      Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

      Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

      Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and according to current clinical practice.

      Androgen deprivation therapy may prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes.

      Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

      Monitor serum levels of testosterone following injection of CAMCEVI.

      Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

      The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

      INDICATION

      CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

      Click here for full Prescribing Information.

      Reference:

      1. CAMCEVI. Prescribing information. Accord BioPharma; May 2021.